Back

Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer

Xu, S.; Li, X.; Peng, Y.; Yang, X.; Su, Y.; Li, H.; Wang, S.; Li, X.; Du, Y.

2025-10-15 cancer biology
10.1101/2025.10.15.682623 bioRxiv
Show abstract

Thyroid cancer is the most common endocrine malignancy, particularly in patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), who have limited treatment options and poor clinical prognosis. In this study, doxorubicin (DOX) and sorafenib (SOR) were loaded into the photothermal conversion agent mesoporous polydopamine (mPDA), forming mPDS. Tumor cell membrane coating engineering resulted in the formation of mPDS@CAR-M, significantly improving tumor targeting. After internalization by tumor cells, the loaded drugs are rapidly released under near-infrared (NIR) laser irradiation. mPDS@CAR-M effectively inhibits tumor cell proliferation by enhancing oxidative stress, suppressing the PI3K-AKT-mTOR signaling pathway, and inducing cytotoxic autophagy. By activating harmful autophagy, mPDS@CAR-M further inhibits the epithelial-mesenchymal transition (EMT) process, reducing tumor cell migration capacity. In vivo experiments showed that mPDS@CAR-M significantly reduced tumor volume, with its therapeutic efficacy closely related to the expression level of the targeted surface antigen. Therefore, mPDS@CAR-M demonstrates significant potential in the treatment of RAIR-DTC, providing a novel direction for further clinical exploration.

Published in Biomaterials Research · not in our set (fewer than 10 published preprints to learn from) · training set

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Journal of Controlled Release
○ 44 papers in training set
Top 0.1%
15.1%
Similar papers in this journal
2
Advanced Science
○ 286 papers in training set
Top 0.7%
6.7%
Similar papers in this journal
3
Advanced Functional Materials
○ 46 papers in training set
Top 0.2%
5.5%
Similar papers in this journal
4
Theranostics
● 37 papers in training set
Top 0.1%
5.5%
Similar papers in this journal
5
ACS Nano
● 113 papers in training set
Top 0.5%
4.3%
Similar papers in this journal
6
Journal of Nanobiotechnology
○ 14 papers in training set
Top 0.1%
4.3%
7
Science Advances
● 1243 papers in training set
Top 8%
4.0%
8
Nature Communications
○ 5641 papers in training set
Top 32%
4.0%
9
Biomaterials
○ 84 papers in training set
Top 0.5%
3.5%
50% of probability mass above
10
Bioactive Materials
○ 20 papers in training set
Top 0.1%
3.4%
11
Advanced Materials
○ 56 papers in training set
Top 0.5%
2.4%
12
ACS Applied Materials & Interfaces
● 39 papers in training set
Top 0.5%
1.9%
13
Materials Today Bio
○ 20 papers in training set
Top 0.3%
1.9%
14
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.5%
1.7%
15
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.8%
1.3%
16
eLife
● 5828 papers in training set
Top 56%
1.3%
17
Communications Biology
○ 993 papers in training set
Top 21%
1.1%
18
Scientific Reports
○ 3612 papers in training set
Top 63%
1.1%
19
Cancers
○ 213 papers in training set
Top 4%
1.1%
20
Small
○ 78 papers in training set
Top 1%
1.1%
21
Molecular Therapy
○ 81 papers in training set
Top 1%
1.0%
22
Molecular Therapy - Nucleic Acids
○ 25 papers in training set
Top 0.6%
1.0%
23
Molecular Therapy Oncology
○ 10 papers in training set
Top 0.2%
0.9%
24
iScience
○ 1154 papers in training set
Top 35%
0.8%
25
International Journal of Molecular Sciences
○ 494 papers in training set
Top 17%
0.6%
26
Lab Animal
○ 11 papers in training set
Top 0.3%
0.6%
27
Advanced Therapeutics
○ 17 papers in training set
Top 0.4%
0.6%
28
ACS Biomaterials Science & Engineering
● 37 papers in training set
Top 1%
0.6%
29
Cell Reports Medicine
○ 153 papers in training set
Top 6%
0.6%
30
PLOS ONE
● 5266 papers in training set
Top 62%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.